Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
lysine clonixinate
- Development stage
- Unknown
- Lead developer
- Recordati
- Modality
- Small Molecules
- Administration
- Intramuscular, Intravenous, Oral
01
Overview
Algimate is a brand name for lysine clonixinate (clonixin lysinate), a non-steroidal anti-inflammatory drug (NSAID) with potent analgesic properties. It is marketed by Jaba Recordati (a subsidiary of Recordati) in Portugal. Lysine clonixinate acts primarily by inhibiting cyclooxygenase (COX) enzymes, specifically COX-1 and COX-2, thereby reducing the synthesis of prostaglandins that mediate pain, fever, and inflammation. It is indicated for the symptomatic treatment of mild to moderate pain of various etiologies, including musculoskeletal pain, postoperative pain, dysmenorrhea, headaches, and dental pain. Algimate is available in oral film-coated tablet and injectable solution formulations.
- Brand names
- AclosinAdoplanAlgimateBlonaxCelexClonalginClonicidolClonixColmaxDisinalDolalgialDolaminDolexDolixDorixina
- Other names
- clonixinclonixin lysinateclonixin lysineclonixina lisinatoclonixino lisina
02
Targets
PGHS-1 (Prostaglandin G/H Synthase 1)ALOX5 (Arachidonate 5-lipoxygenase)
Beyond the preview
Go deeper on lysine clonixinate.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on lysine clonixinate.